Holen Sie sich die Stockscreener-App
0.8073
3.61%
0.0281
Handel nachbörslich:
.82
0.0127
+1.57%
Schlusskurs vom Vortag:
$0.7792
Offen:
$0.771
24-Stunden-Volumen:
57,716
Relative Volume:
0.37
Marktkapitalisierung:
$10.34M
Einnahmen:
$41.71M
Nettoeinkommen (Verlust:
$-10.54M
KGV:
-0.6867
EPS:
-1.1757
Netto-Cashflow:
$-13.36M
1W Leistung:
+0.91%
1M Leistung:
-23.84%
6M Leistung:
+9.12%
1J Leistung:
+20.89%
1-Tages-Spanne:
$0.771
$0.83
1-Wochen-Bereich:
$0.7304
$0.8526
52-Wochen-Spanne:
$0.536
$1.19
Biofrontera Inc Stock (BFRI) Company Profile
Firmenname
Biofrontera Inc
Sektor
Telefon
781-245-1325
Adresse
120 PRESIDENTIAL WAY,, WOBURN
Compare BFRI vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.8073 | 9.98M | 41.71M | -10.54M | -13.36M | -1.1757 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Biofrontera Inc Aktie (BFRI) Neueste Nachrichten
BFRI Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid No Reported RevenueForward EPS Estimate - Newser
Biofrontera (BFRI) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin as Stock RisesRising Community Picks - Newser
Biofrontera to present at Lytham Partners Spring 2026 Investor Conference on May 28 - Pluang
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - The Manila Times
BFRI Downgraded by Benchmark -- Rating Maintained as Speculative Buy - GuruFocus
This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Biofrontera stock rating cut to Speculative Buy by Benchmark - Investing.com
Benchmark Downgrades Biofrontera to Speculative Buy From Buy, Price Target is $3 - marketscreener.com
Benchmark Co. Maintains Biofrontera(BFRI.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Benchmark Downgrades Biofrontera to Speculative Buy From Buy, Price Target Is $3 - Moomoo
Biofrontera (BFRI) Climbs +1.45% — Resistance at $0.85 in Focus 2026-05-19Most Watched Stocks - newser.com
Biofrontera (BFRI) Reports Strong Q1 Growth and Improved Profita - GuruFocus
Biofrontera posts strong 17% revenue growth but wider Q1 loss than expected - Pluang
Biofrontera Inc. 1Q 2026: Revenue $10.08M, EPS $(0.41) — 10-Q Summary - TradingView
Biofrontera (BFRI) Q1 2026: revenue up 17% but going concern and ITC hit - Stock Titan
Biofrontera targets cash flow breakeven in 2026 while aiming for 80%-85% gross margin - MSN
BFRI: Q1 2026 delivered 17% revenue growth, 80% gross margin, and major clinical pipeline progress - TradingView
Earnings call transcript: Biofrontera Q1 2026 sees gross margin leap - Investing.com
BFRI: Revenue up 17%, gross margin at 80%, and clinical pipeline advancing toward key milestones - TradingView
Biofrontera Inc. (BFRI) reports Q1 loss, beats revenue estimates - MSN
Biofrontera Inc. Reports 17% Revenue Growth and Improved Gross Margins in Q1 2026, Advances Dermatology Pipeline - Minichart
Earnings call transcript: Biofrontera Q1 2026 sees gross margin leap By Investing.com - Investing.com Canada
Transcript: Biofrontera Q1 2026 Earnings Conference Call - Benzinga
Biofrontera Q1 2026 Earnings Call Transcript - MarketBeat
Biofrontera Inc. (NASDAQ:BFRI) Reports Q1 2026 Revenue and EPS Miss, Stock Falls in Pre-Market - ChartMill
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
BIOFRONTERA ($BFRI) Releases Q1 2026 Earnings - Quiver Quantitative
Biofrontera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Biofrontera Reports Q1 2026: Revenue $10.1M, Gross Margin ~80%, Adjusted EBITDA $(3.6)M - TradingView
Biofrontera (NASDAQ: BFRI) grows Q1 revenue, boosts margins and advances Ameluz - Stock Titan
Biofrontera 1Q Loss/Shr 41c >BFRI - Moomoo
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update - The Manila Times
BFRI: Revenue up 17% and gross margin reached 80% in Q1 2026, with strong Ameluz sales momentum - TradingView
Biofrontera Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biofrontera Launches Second Annual 'Hats On” Campaign to Raise Awareness of Actinic Keratosis - The Manila Times
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis - GlobeNewswire
Biofrontera Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
TradingKey - tradingkey.com
Draganfly to Host Shareholder Update Call on May 11, 2026 - Weekly Voice
How Biofrontera (BFRI) integrates its acquisitions | Q4 2025: EPS Beats ForecastsCrowd Entry Signals - Newser
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026 - The Manila Times
Biofrontera to post March-quarter results after market close May 14 - Stock Titan
Biofrontera Inc. to Announce Q1 2026 Financial Results on May 14 - geneonline.com
Equity incentives and director votes at Biofrontera (NASDAQ: BFRI) 2026 meeting - Stock Titan
Biofrontera : Proxy of the Company (Proxy of the Company) - marketscreener.com
BFRI - Finviz
Biofrontera sees Q4 2025 net sales of about $17M to $17.5M - MSN
BFRI Biofrontera posts strong Q4 2025 EPS beat, shares dip 0.91% as investors weigh long-term growth risks.Crowd Sentiment Stocks - Xã Thanh Hà
Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Biofrontera : Annual report 2025 (Annual report 2025) - marketscreener.com
PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FINANCIAL YEAR 2025 - TradingView
Finanzdaten der Biofrontera Inc-Aktie (BFRI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.92%
4.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):